

Special Issue

Chronic Kidney and Liver Disease: From Pathophysiology to Novel Therapeutic Approaches 2.0

Message from the Guest Editor

The prevalence of chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) is on the rise, and it is expected that both diseases will become leading causes of death globally. CKD is defined by a long-standing loss of renal function and is associated with an increased risk of end-stage renal disease, cardiovascular disease and premature death. NAFLD is characterized by excessive fat accumulation in the liver, and it covers a spectrum of diseases, from simple steatosis to the more aggressive form of non-alcoholic steatohepatitis (NASH). Both CKD and NAFLD share risk factors that are increasingly prevalent. Consequently, both diseases frequently exist together. Yet, studies on the mechanistic link between CKD and NAFLD are sparse. To improve clinical care, a better understanding of the pathophysiological mechanisms that underlie the development and progression of both CKD and NAFLD is essential. For this Special Issue we welcome papers that focus on the pathogenesis of CKD, NAFLD and associated pathologies, in addition to papers detailing novel therapeutic targets and therapies. Papers that investigate the link between both diseases are especially welcomed.

Guest Editor

Dr. Henricus A.M. Mutsaers

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Deadline for manuscript submissions

closed (15 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/109836

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).